Diagnostic Value of CT Delayed Phase Images Added to Gd-EOB-DTPA MRI for HCC Diagnosis in LR-3/4 Lesions

References

• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Zhang CH, Cheng Y, Zhang S, et al. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2029–2041. doi:10.1111/liv.15251
   PubMed Web of Science ®Google Scholar
• Sperber A, Bangdiwala S, Drossman D, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3. doi:10.1053/j.gastro.2020.04.014
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Tang A, Singal AG, Mitchell DG, et al. Introduction to the liver imaging reporting and data system for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2019;17(7):1228–1238. doi:10.1016/j.cgh.2018.10.014
   PubMed Web of Science ®Google Scholar
• Kanmaniraja D, Dellacerra G, Holder J, et al. Liver imaging reporting and data system (LI-RADS) v2018: review of the CT/MRI diagnostic categories. Can Assoc Radiol J. 2021;72(1):142–149. doi:10.1177/0846537119888393
   PubMed Web of Science ®Google Scholar
• Kang JH, Choi SH, Byun JH, et al. Ancillary features in the liver imaging reporting and data system: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging. Eur Radiol. 2020;30(5):2881–2889. doi:10.1007/s00330-019-06645-3
   PubMed Web of Science ®Google Scholar
• Agnello F, Albano D, Sparacia G, et al. Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up. Clin Imaging. 2020;68:169–174. doi:10.1016/j.clinimag.2020.08.003
   PubMed Web of Science ®Google Scholar
• Vernuccio F, Cannella R, Choudhury KR, et al. Hepatobiliary phase hypointensity predicts progression to hepatocellular carcinoma for intermediate-high risk observations, but not time to progression. Eur J Radiol. 2020;128:109018. doi:10.1016/j.ejrad.2020.109018
   PubMed Web of Science ®Google Scholar
• Zech CJ, Ba-Ssalamah A, Berg T, et al. Consensus report from the 8th international forum for liver magnetic resonance imaging. Eur Radiol. 2020;30(1):370–382. doi:10.1007/s00330-019-06369-4
   PubMed Web of Science ®Google Scholar
• Murakami T, Sofue K, Hori M. Diagnosis of hepatocellular carcinoma using Gd-EOB-DTPA MR imaging. Magn Reson Med Sci. 2022;21(1):168–181. doi:10.2463/mrms.rev.2021-0031
   PubMed Web of Science ®Google Scholar
• American College of Radiology. LI-RADS version 2018. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-DataSystems/LI-RADS/CT-MRI-LI-RADS-v2018. Accessed June 6, 2023.
   Google Scholar
• Baek KA, Kim SS, Shin HC, et al. Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout? Abdom Radiol. 2020;45(9):2705–2716. doi:10.1007/s00261-020-02553-z
   PubMed Web of Science ®Google Scholar
• Song JS, Choi EJ, Hwang SB, et al. LI-RADS v2014 categorization of hepatocellular carcinoma: intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI. Eur Radiol. 2019;29(1):401–410. doi:10.1007/s00330-018-5559-z
   PubMed Web of Science ®Google Scholar
• Joo I, Kim H, Lee JM. Cancer stem cells in primary liver cancers: pathological concepts and imaging findings. Korean J Radiol. 2015;16(1):50–68. doi:10.3348/kjr.2015.16.1.50
   PubMed Web of Science ®Google Scholar
• Kim DH, Choi SH, Kim SY, et al. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases. Radiology. 2019;291(3):651–657. doi:10.1148/radiol.2019182587
   PubMed Web of Science ®Google Scholar
• Kim TH, Kim SY, Tang A, et al. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol. 2019;25(3):245–263. doi:10.3350/cmh.2018.0090
   PubMed Web of Science ®Google Scholar
• Allen BC, Ho LM, Jaffe TA, et al. Comparison of visualization rates of li-rads version 2014 major features with iv gadobenate dimeglumine or gadoxetate disodium in patients at risk for hepatocellular carcinoma. AJR Am J Roentgenol. 2018;210:1266–1272. doi:10.2214/AJR.17.18981
   PubMed Web of Science ®Google Scholar
• Jiang H, Song B, Qin Y, et al. Data-driven modification of the LI-RADS major feature system on gadoxetate disodium-enhanced MRI: toward better sensitivity and simplicity. J Magn Reson Imaging. 2022;55(2):493–506. doi:10.1002/jmri.27824
   PubMed Web of Science ®Google Scholar
• Cha DI, Choi GS, Kim YK, et al. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS. Eur Radiol. 2020;30(7):3723–3734. doi:10.1007/s00330-020-06753-5
   PubMed Web of Science ®Google Scholar
• Cerny M, Bergeron C, Billiard JS, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology. 2018;288(1):118–128. doi:10.1148/radiol.2018171678
   PubMed Web of Science ®Google Scholar
• Kierans AS, Makkar J, Guniganti P, et al. Validation of liver imaging reporting and data system 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging. 2019;49(7):e205–e215. doi:10.1002/jmri.26329
   PubMed Web of Science ®Google Scholar
• Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology. 2009;250(2):435–443. doi:10.1148/radiol.2501071702
   PubMed Web of Science ®Google Scholar
• An C, Rhee H, Han K, et al. Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma. Eur Radiol. 2017;27(6):2610–2618. doi:10.1007/s00330-016-4634-6
   PubMed Web of Science ®Google Scholar
• Chong HH, Yang L, Sheng RF, et al. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm. Eur Radiol. 2021;31(7):4824–4838. doi:10.1007/s00330-020-07601-2
   PubMed Web of Science ®Google Scholar
• Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72–81. doi:10.1016/j.ejrad.2018.01.025
   PubMed Web of Science ®Google Scholar
• Choi BI, Lee JM, Kim TK, et al. Diagnosing borderline hepatic nodules in hepatocarcinogenesis: imaging performance. AJR Am J Roentgenol. 2015;205(1):10–21. doi:10.2214/AJR.14.12655
   PubMed Web of Science ®Google Scholar
• Vander Pol CB, Dhindsa K, Shergill R, et al. MRI LI-RADS version 2018: impact of and reduction in ancillary features. AJR Am J Roentgenol. 2021;216(4):935–942. doi:10.2214/AJR.20.23031
   PubMed Web of Science ®Google Scholar
• Narsinh KH, Cui J, Papadatos D, et al. Hepatocarcinogenesis and LI-RADS. Abdom Radiol. 2018;43(1):158–168. doi:10.1007/s00261-017-1409-8
   PubMed Web of Science ®Google Scholar
• Jang HJ, Kim TK, Burns PN, et al. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology. 2007;244(3):898–906. doi:10.1148/radiol.2443061520
   PubMed Web of Science ®Google Scholar
• Okamoto D, Yoshimitsu K, Nishie A, et al. Enhancement pattern analysis of hypervascular hepatocellular carcinoma on dynamic MR imaging with histopathological correlation: validity of portal phase imaging for predicting tumor grade. Eur J Radiol. 2012;81(6):1116–1121. doi:10.1016/j.ejrad.2011.02.056
   PubMed Web of Science ®Google Scholar
• Nakao S, Tanabe M, Okada M, et al. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging. Jpn J Radiol. 2019;37(9):651–659. doi:10.1007/s11604-019-00855-x
   PubMed Web of Science ®Google Scholar
• Min JH, Kim JM, Kim YK, et al. Magnetic resonance imaging with extracellular contrast detects hepatocellular carcinoma with greater accuracy than with gadoxetic acid or computed tomography. Clin Gastroenterol Hepatol. 2020;18(9):2091–2100.e7. doi:10.1016/j.cgh.2019.12.010
   PubMed Web of Science ®Google Scholar